Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $125 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
- Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
- Mirum’s brelovitug succeeds in Phase 2b HDV trial
- Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
- Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC